A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy

Phase 1

Recruiting

• Conditions: Limited Stage Small Cell Lung Cancer; Not Progressed After First-line Chemoradiotherapy
• Interventions: Drug: TQB2450 Injection + Anlotinib Hydrochloride Capsules

• Registration Number: NCT05942508
• Lead Sponsor: Jinming Yu

Brief Summary

To assess the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell lung cancer who do not progress after first-line chemoradiotherapy. Based on the incidence and severity of benign and serious adverse events, as well as abnormal laboratory

Detailed Description

Not available

Study Timeline

• Study Start: 2023-05-30
• Study First Submitted: 2023-06-07
• Status Verified: 2023-07
• Study First Submitted QC: 2023-07-05
• Last Update Submitted: 2023-07-05
• Study First Posted: 2023-07-12
• Last Update Posted: 2023-07-12
• Primary Completion: 2026-02
• Study Completion: 2026-02

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• The subject voluntarily joins the study, signs the informed consent form, and has good compliance;
• Age: 18~75 years old (when signing the informed consent form); ECOG PS score: 0-1 points; Expected survival beyond 6 months; body weight> 40 kg;
• Patients with pathologically confirmed limited-stage small cell lung cancer (according to the Veterans Administration Lung Study Group (VALG stage);
• Through the neck, chest, abdomen, pelvic enhanced CT and brain plain scan + enhanced MRI examination with diagnostic quality, there is no evidence of metastatic disease (PET-CT examination is recommended before starting radiotherapy and chemotherapy, if not performed before radiotherapy and chemotherapy PET-CT examination, bone scan examination should be performed; PET-CT examination must be performed during the screening period after chemoradiotherapy to exclude metastasis);
• It is expected that no tumor resection will be required during the study (patients who are not suitable for surgery or those who are unwilling to undergo surgery are acceptable);
• Radiotherapy technology adopts three-dimensional conformal radiotherapy, conformal intensity-modulated radiotherapy, tomographic radiation therapy and other precision radiotherapy technologies;
• Patients must achieve CR, PR or SD after receiving radical platinum-based CRT and cannot develop disease progression;
• Patients with at least one measurable lesion confirmed according to RECIST 1.1 criteria prior to chemoradiotherapy;

Exclusion Criteria

• Complex small cell lung cancer confirmed by histopathology or cytopathology;
• Subjects with known central nervous system metastasis and/or cancerous meningitis;
• Malignant pleural effusion and pericardial effusion;
• Imaging shows that the tumor has invaded important blood vessels, or the researcher has determined that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies;
• Within 2 weeks before the start of the study treatment, he has received the treatment of traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the NMPA approved drug manual;
• Patients who have received immunomodulatory drugs within 30 days before starting treatment;
• Previously received anti PD-1, anti PD-L1, or anti PD-L2 drugs or medication targeting another stimulating or co inhibitory T cell receptor;
• Previous use of antivascular survival drugs（ bevacizumab, arotinib, apatinib ,ect);

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
TQB2450 Injection + Anlotinib Hydrochloride Capsules	TQB2450 Injection + Anlotinib Hydrochloride Capsules	TQB2450 injection: 1200 mg/time, intravenous drip, day 1, Q3W; Anlotinib Hydrochloride Capsules: 8 mg/dose, once daily (QD), continuously used for 2 weeks, stopped for 1 week, and taken orally before breakfast (the starting dose of Anlotinib Hydrochloride is 8 mg, and it is allowed to be increased to 10 mg after two cycles of use)

Primary Outcome Measures

Name	Time	Method
serious adverse event	Start from the first dose until the last dose to within 84 days after the last dose or start new target indication treatment (whichever occurs first)	Incidence and Severity of Serious Adverse Events
Adverse event	Start from the first dose until the last dose to within 84 days after the last dose or start new target indication treatment (whichever occurs first)	Incidence and severity of adverse events

Secondary Outcome Measures

Name	Time	Method
Overall response rate (ORR)	Up to approximately 36 months	ORR:According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.the proportion of subjects whose tumors are evaluated as complete response(CR) and partial response(PR) by subcenter imaging evaluation. It is recorded from the first use of the drug to disease progression or initiation of a new anticancer treatment.
disease control rate	Up to approximately 36 months	The percentage of patients who have achieved remission or stable changes in their condition after treatment compared to the evaluable cases
duration of remission	Up to approximately 36 months	The time from the first assessment of the tumor as CR or PR to the first assessment as PD (Progressive Disease) or death from any cause

Trial Locations

Locations (1)

Cancer Hospital Affiliated to Shandong First Medical University; 🇨🇳 Jinan, Shandong, China